A-Z Search Jobs Add entry Licensing Solutions Register Log in Site Info GW Pharmaceuticals Plc GW Pharmaceuticals operates under UK Government licences in the development of prescription medicines derived from the cannabis plant. Clinical trials of cannabis-based medicines are about to start in Guernsey. I study profile GW Pharmaceuticals operates under UK Government licences in the development of prescription medicines derived from the cannabis plant.
Research is also ongoing into the neuroprotective and immunomodulatory effects of cannabinoids.
In recent years, the cannabinoid receptors CB1 and CB2 have been identified and a number of endogenous cannabinoids discovered. The interaction of various cannabinoids in different ratios is believed to provide a range of therapeutic effects. In addition to the considerable amount of compelling basic laboratory research demonstrating the therapeutic potential of cannabinoid medicines, there is extensive evidence from large numbers of patients that report benefit from using illicit cannabis. Based on this evidence as well as further in-house research, GW is developing a broad product portfolio which includes products targeted at multiple sclerosis, spinal cord injury, neurogenic pain, spasticity and other neurological dysfunction, arthritis, migraine, head injury, schizophrenia, weight loss associated with cancer and AIDS, and chemotherapy induced nausea and vomiting. Timelines for drug approval and launch for GW are expected to be considerably shorter than for new chemical entities.